Increased Expression Of Interleukin-23a In Lesional Skin Of Patients With Atopic Dermatitis With Psoriasiform Reaction During Dupilumab Treatment

Atopic dermatitis (AD) and psoriasis (Pso) are chronic diseases that may be phenotypes at polar ends of the T-cell inflammatory milieu. The two diseases represent two distinct pathogenetic entities, with type 2 T helper (Th2) cytokines interleukin (IL)-4, IL-13, IL-31, and possibly IL-22 mainly implicated in AD, and Th17 cytokines IL-17 and IL-23 in Pso. However, a range of phenotypes with overlapping clinical patterns exist, possibly reflecting a variable expression of T-cell axes. Dupilumab is a human monoclonal antibody directed against the alpha subunit of IL-4 receptor, approved for the treatment of moderate-to-severe AD.